Enter your keywords
To search AlzRisk, use the "Keyword" search on the
AlzRisk search page
Papers of the Week
The HBO Alzheimer's Project
My AlzForum Home
AlzRisk Paper Detail
Non-Steroidal Anti-Inflammatory Drugs
The investigators ascertained exposure information by accessing pharmacy records which were available after July 1991. They obtained information on filled prescriptions for all participants. The investigators reported results separately for ever/never statin use, lipophilic statin use, non-lipohilic statin use, duration of use, and dosage of use. This entry pertains to results on the median defined daily dose (DDD) of statin use.
The investigators compared incident AD risk in two separate sets of comparison groups: the group of participants whose dosage of statin use was less than or equal to the median dosage of 0.89 ("≤ median dosage") and the reference group of participants who did not use statins or any cholesterol lowering drugs prior to the event date ("Never used"); and separately, the group of participants whose dosage of statin use was greater than the median dosage of 0.89 ("> Median dosage") and the reference group of participants who did not use statins or any cholesterol lowering drugs prior to the event date ("Never used"). Approximately 2% of participants had used or were using statins at the time of diagnosis. The article does not mention the exposure distribution in regard to statin dosage for the study cohort.
All participants were residents of the Ommoord district of Rotterdam. No other information regarding ethnicity was given.
All participants were 55 years of age or older.
Screening and Diagnosis Detail
Cambridge Examination for Mental Disorders of the Elderly
Geriatric Mental State Schedule (Copeland 1976)
Mini-Mental State Examination (Folstein 1975)
Diagnostic and Statistical Manual III-Revised
National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association Criteria (McKhann 1984)
Total dementia definition:
Dementia via DSM-IIIR
A panel consisting of a neurologist, neurophysiologist, and a research physician made diagnoses using a three step process. Participants who had a MMSE score of less than 26 or GMS organic level greater than 0 were considered screen-positives and were asked to take the CAMDEX exam, neurological testing and imaging (if available). The panel made diagnoses of dementia and its subtypes by using DSMIII-R and NINCDS-ADRDA criteria.
Covariates & Analysis Detail
Cox proportional hazards regression
body mass index
systolic blood pressure
use of a cholesterol-lowering drug other than a statin